Teva Pharmaceutical Industries (NYSE:TEVA) CEO Richard Francis Sells 250,000 Shares of Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) CEO Richard Francis sold 250,000 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $42.24, for a total value of $10,560,000.00. Following the completion of the transaction, the chief executive officer directly owned 927,529 shares of the company’s stock, valued at approximately $39,178,824.96. This trade represents a 21.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Teva Pharmaceutical Industries Stock Up 0.7%

Shares of NYSE:TEVA opened at $43.52 on Friday. The company has a market capitalization of $50.72 billion, a price-to-earnings ratio of 101.22, a P/E/G ratio of 4.05 and a beta of 0.97. The company has a debt-to-equity ratio of 1.59, a current ratio of 0.95 and a quick ratio of 0.74. The business’s 50-day moving average is $40.00 and its 200-day moving average is $35.01. Teva Pharmaceutical Industries Ltd. has a 1 year low of $24.01 and a 1 year high of $44.31.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Tuesday, November 3rd. The company reported $0.86 EPS for the quarter, topping the consensus estimate of $0.72 by $0.14. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The business had revenue of $4.39 billion during the quarter, compared to analysts’ expectations of $4.23 billion. During the same quarter last year, the firm posted $0.78 earnings per share. The firm’s revenue was down 1.9% on a year-over-year basis. Equities research analysts predict that Teva Pharmaceutical Industries Ltd. will post 1.98 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently commented on TEVA shares. JPMorgan Chase & Co. raised their price objective on shares of Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the stock an “overweight” rating in a research report on Monday, October 12th. Oppenheimer boosted their target price on shares of Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the company an “outperform” rating in a research report on Friday, October 9th. Leerink Partners increased their target price on shares of Teva Pharmaceutical Industries from $45.00 to $52.00 and gave the stock an “outperform” rating in a research note on Thursday, November 5th. UBS Group raised their price target on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a “buy” rating in a report on Friday, September 4th. Finally, Barclays lifted their price target on shares of Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the company an “overweight” rating in a research note on Thursday, October 15th. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $48.15.

Institutional Trading of Teva Pharmaceutical Industries

Several hedge funds have recently bought and sold shares of the business. Root Financial Partners LLC bought a new stake in Teva Pharmaceutical Industries during the 3rd quarter valued at $33,000. Cornerstone Planning Group LLC lifted its stake in shares of Teva Pharmaceutical Industries by 547.1% in the first quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock valued at $27,000 after buying an additional 755 shares in the last quarter. Western Wealth Management LLC bought a new position in shares of Teva Pharmaceutical Industries in the first quarter valued at $43,000. Sunbelt Securities Inc. acquired a new position in shares of Teva Pharmaceutical Industries during the first quarter valued at about $45,000. Finally, CX Institutional acquired a new position in shares of Teva Pharmaceutical Industries during the second quarter valued at about $54,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries News Roundup

Here’s some of the latest news about TEVA:

• Positive Sentiment: Piper Sandler raised its price target to $56 from $44 and reiterated an Overweight rating, signaling confidence in further upside. Piper Sandler analyst ratings
• Neutral Sentiment: Healthcare stocks broadly declined Wednesday afternoon, a sector headwind that may have affected trading but does not reflect Teva-specific fundamentals. Healthcare sector update
• Negative Sentiment: CEO Richard Francis sold 250,000 shares for about $10.6 million, reducing his stake by 21.23%. EVP Richard Daniell also sold 20,003 shares and 25,000 shares in separate transactions. These sizable insider sales may raise concerns about executive confidence, although the filings do not state the reasons for the transactions. CEO SEC filing EVP SEC filing

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.